Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (gefitinib, erlotinib and afatinib) are indicated as first-line therapy in individuals with non-small cell lung cancer (NSCLC) whose tumors harbor activating mutations in the EGFR gene. of the miR-133b mimic in A549 and H1299 NSCLC cell lines indicated that raising miR-133b manifestation level resulted in a reduced… Continue reading Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (gefitinib, erlotinib and